Leukemia/BMT

 Print this Page

The information contained in these documents is a statement of consensus of BC Cancer Agency professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is at your own risk and is subject to BC Cancer Agency's terms of use available at www.bccancer.bc.ca/legal.htm .

PLEASE NOTE: All links in the table below open PDF documents.

PROTOCOL CODE and DESCRIPTION	AVAILABLE DOCUMENTS (revision date indicated in red)
BMTMM0301: Conditioning therapy for autologous stem cell transplant using high dose melphalan in the treatment of multiple myeloma.	- Protocol (01 May 2009)
BMTIVBUCY: Myeloablative conditioning therapy prior to autologous and allogeneic hematopoietic stem cell transplantation for myeloid malignancies using IV busulfan and cyclophosphamide.	- Protocol (01 May 2009)
CMLIFNCYT: Therapy of chronic myeloid leukemia using interferon and cytarabine.	- Protocol (01 May 2009)
LKANAG: Anagrelide as second-line treatment of thrombocytosis related to myeloproliferative disorders.	- Protocol (01 May 2009)
LKCMLI: Therapy for chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia using imatinib.	- Protocol (01 Feb 2010)  - Preprinted Order (01 Feb 2010)  - Patient Handout (01 Feb 2010)
ULKCMLD: Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using Dasatinib (SPRYCEL®)	- Protocol (01 Feb 2010)  - Preprinted Order (01 Feb 2010)  - Patient Handout (01 Feb 2010)
ULKCMLN: Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using Nilotinib	- Protocol (01 Feb 2010) - Preprinted Order (01 Feb 2010) - Patient Handout (01 Feb 2010)
ULKMDSL: Therapy of Myelodysplastic Syndrome using Lenalidomide.	- Protocol (01 Aug 2009) -  Preprinted Order (01 Dec 2009)
LYCODOXMR: Treatment of Burkitt’s Lymphoma and Leukemia (ALL-L3) with Cyclophosphamide, Vincristine, Doxorubicin, Methotrexate, Leucovorin (CODOX-M) and Rituximab	see Lymphoma page
LYIVACR: Treatment of Burkitt’s Lymphoma and Leukemia (ALL-L3) with Ifosfamide, Mesna, Etoposide, Cytarabine (IVAC) and Rituximab	see Lymphoma page
MYHDC: Single dose cyclophosphamide priming therapy for multiple myeloma prior to autologous stem cell transplant.	- Protocol (01 Dec 2009)